Hemostemix Inc. (TSXV: HEM / OTC: HMTXF) – Awaiting Results of Phase II Trials of a Potential Therapy for Cardiovascular Diseases – Initiating Coverage
Based out of Alberta, this company is a clinical-stage (pre-revenue) biotechnology company in phase II trials. Its patented process uses autologous stem cell therapy, wherein stem cells are sourced from a patient’s own blood. Harvested stem cells are processed, multiplied, and reintroduced to the patient’s body to repair damaged and/or dysfunctional tissues/organs.
This report is currently available to premium subscribers – Free subscribers will gain access on Aug 31st, 2022
Join as a FREE member and get our research report delivered straight to your inbox, with a seven-day delay
Visit Hemostemix Inc. page for more research, discussion boards and to like, and share.
